Evidence map›Paper›PMID 29579256›Full record

ArticleThe Journal of infectious diseases2018

Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection.

Deogratius Ssemwanga, Nicole A Doria-Rose, Andrew D Redd, Andrea R Shiakolas, Andrew F Longosz, Rebecca N Nsubuga, Billy N Mayanja, Gershim Asiki, Janet Seeley, Anatoli Kamali and 10 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

Deogratius SsemwangaUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Nicole A Doria-RoseVaccine Research Center.
Andrew D ReddLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.
Andrea R ShiakolasVaccine Research Center.
Andrew F LongoszLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.
Rebecca N NsubugaUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Billy N MayanjaUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Gershim AsikiUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Janet SeeleyUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Anatoli KamaliUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Amy RansierVaccine Research Center.
Samuel DarkoVaccine Research Center.
Michael P WalkerGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, NIAID, NIH, Hamilton, Montana.
Daniel BrunoGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, NIAID, NIH, Hamilton, Montana.
Craig MartensGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, NIAID, NIH, Hamilton, Montana.
Daniel DouekVaccine Research Center.
Stephen F PorcellaGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, Division of Intramural Research, NIAID, NIH, Hamilton, Montana.
Thomas C QuinnLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda.
John R MascolaVaccine Research Center.
Pontiano KaleebuUganda Research Unit on AIDS, Medical Research Council/Uganda Virus Research Institute, Entebbe.
Uganda Virus Research Institute · UGJohns Hopkins Medicine · USNational Institute of Allergy and Infectious Diseases · US

Funding

Infectious Diseases Research Technologies Core - RMLZICAI001052 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$133.3M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Determination of the Neutralization Specificity in Broadly Neutralizing HIV SeraZIAAI005089 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MASCOLA, JOHN · 2009 to 2018
$9.6M
IMMUNOLOGICAL AND VIRAL FACTORS ASSOCIATED WITH HIV-1 SUPERINFECTIONR01AI118368 · NIAID · UGANDA VIRUS RESEARCH INSTITUTE · PI KALEEBU, PONTIANO · 2015 to 2019
$677k
Medical Research Council MC_U950097145Medical Research Council MC_UP_1204/2Medical Research Council MC_UU_00027/1
6 · The paper itself

Abstract

This report describes the identification of a genetically confirmed linked heterosexual human immunodeficiency virus (HIV) superinfection (HIV-SI) in a woman with chronic HIV infection who acquired a second strain of the virus from her husband. Serum neutralizing antibody (NAb) responses against their homologous and heterologous viruses, including the superinfecting strain, in the woman and her husband were examined before and after onset of HIV-SI. The woman displayed a moderately potent and broad anti-HIV NAb response prior to superinfection but did not possess NAb activity against the superinfecting strain. This case highlights the unique potential of linked HIV-SI studies to examine natural protection from HIV infection.

Indexed as

Antibodies, NeutralizingAntibody FormationFemaleHeterosexualityHIV-1HIV AntibodiesHIV InfectionsHumansMaleNeutralization TestsSuperinfectionAntibodies, NeutralizingHIV Antibodies

Identifiers

PMID29579256
PMCPMC6065500
OpenAlexW2794402702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.